1. Biological drugs in the treatment of atopic dermatitis – current recommendations of the Polish Dermatological Society, the Polish Society of Allergology, the Polish Pediatric Society and the Polish Society of Family Medicine
- Author
-
Rafał Czajkowski, Zbigniew Samochocki, Lidia Rudnicka, Elżbieta Grubska-Suchanek, Agnieszka Mastalerz-Migas, Aleksandra Lesiak, Magdalena Trzeciak, Marek Kulus, Jarosław Peregud-Pogorzelski, Malgorzata Olszewska, Cezary Kowalewski, Magdalena Czarnecka-Operacz, Joanna Narbutt, Beata Kręcisz, Aleksandra Wilkowska, Jacek C Szepietowski, Karina Jahnz-Różyk, Radosław Śpiewak, Dorota Krasowska, Roman Nowicki, and Maciej Kupczyk
- Subjects
medicine.medical_specialty ,Allergy ,Dermatology ,Disease ,therapeutic recommendations ,Biological drugs ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,dupilumab ,medicine ,Severe atopic dermatitis ,Immunology and Allergy ,Intensive care medicine ,Internal medicine ,atopic dermatitis ,business.industry ,Incidence (epidemiology) ,Atopic dermatitis ,medicine.disease ,RC31-1245 ,Dupilumab ,RL1-803 ,Special Paper ,business ,Developed country ,biological drugs - Abstract
Atopic dermatitis (AD) is secondary to genetic, immunological and microbiological disorders as well as epidermal barrier defects, which are the main targets of therapy. The disease proceeds with periodic exacerbations. Its development and course are influenced by numerous environmental and individual factors. In recent decades, in industrialized countries, there has been a threefold increase in the incidence of AD. There is also an increasing number of cases resistant to topical treatment. Effective treatment of AD should provide control of clinical symptoms, prevent exacerbations and improve the quality of life of patients. The multifactorial etiopathogenesis and various endotypes and phenotypes of AD justify the tendency to optimize and personalize the therapy. Currently, we recommend the use of dupilumab for the treatment of patients from 12 years of age with moderate and severe atopic dermatitis, who do not respond to topical treatment.
- Published
- 2020